220 related articles for article (PubMed ID: 15008721)
1. Prediction of prostate cancer in extended-field biopsies of the prostate.
Winkler MH; Kulinskaya E; Gillatt DA
BJU Int; 2004 Mar; 93(4):516-21. PubMed ID: 15008721
[TBL] [Abstract][Full Text] [Related]
2. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
[TBL] [Abstract][Full Text] [Related]
3. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL.
Okegawa T; Kinjo M; Watanabe K; Noda H; Kato M; Miyata A; Murata A; Yoshii M; Nutahara K; Higashihara E
BJU Int; 2000 Apr; 85(6):708-14. PubMed ID: 10759671
[TBL] [Abstract][Full Text] [Related]
4. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis.
Taneja SS; Hsu EI; Cheli CD; Walden P; Bartsch G; Horninger W; Babaian RJ; Fritsche HA; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Lepor H
Urology; 2002 Oct; 60(4 Suppl 1):10-7. PubMed ID: 12384157
[TBL] [Abstract][Full Text] [Related]
5. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
[TBL] [Abstract][Full Text] [Related]
6. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
[TBL] [Abstract][Full Text] [Related]
7. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
8. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer.
Maeda H; Arai Y; Aoki Y; Okubo K; Okada T; Maekawa S
Urology; 1999 Aug; 54(2):225-8. PubMed ID: 10443715
[TBL] [Abstract][Full Text] [Related]
9. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Naya Y; Stamey TA; Cheli CD; Partin AW; Sokoll LJ; Chan DW; Brawer MK; Taneja SS; Lepor H; Bartsch G; Childs S; Fritsche HA; Babaian RJ
Urology; 2002 Oct; 60(4 Suppl 1):36-41. PubMed ID: 12384161
[TBL] [Abstract][Full Text] [Related]
10. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
11. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
Okegawa T; Noda H; Nutahara K; Higashihara E
Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
[TBL] [Abstract][Full Text] [Related]
13. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?
Okihara K; Ukimura O; Nakamura T; Mizutani Y; Kawauchi A; Naya Y; Uchida M; Ogiwara T; Miki T
Eur Urol; 2004 Jul; 46(1):57-64. PubMed ID: 15183548
[TBL] [Abstract][Full Text] [Related]
14. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
16. Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.
Veltri RW; Miller MC; O'dowd GJ; Partin AW
Urology; 2002 Oct; 60(4 Suppl 1):47-52. PubMed ID: 12384163
[TBL] [Abstract][Full Text] [Related]
17. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
18. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
[TBL] [Abstract][Full Text] [Related]
20. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
Bangma CH; Kranse R; Blijenberg BG; Schröder FH
Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
